Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lineage Cell Therapeutics (LCTX) Operating Income: 2010-2025

Historic Operating Income for Lineage Cell Therapeutics (LCTX) over the last 15 years, with Sep 2025 value amounting to -$3.8 million.

  • Lineage Cell Therapeutics' Operating Income rose 1.41% to -$3.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$35.2 million, marking a year-over-year decrease of 54.78%. This contributed to the annual value of -$21.5 million for FY2024, which is 13.16% up from last year.
  • Per Lineage Cell Therapeutics' latest filing, its Operating Income stood at -$3.8 million for Q3 2025, which was up 80.86% from -$19.8 million recorded in Q2 2025.
  • Lineage Cell Therapeutics' Operating Income's 5-year high stood at -$3.8 million during Q3 2025, with a 5-year trough of -$28.2 million in Q4 2021.
  • In the last 3 years, Lineage Cell Therapeutics' Operating Income had a median value of -$6.4 million in 2023 and averaged -$6.9 million.
  • Per our database at Business Quant, Lineage Cell Therapeutics' Operating Income crashed by 380.07% in 2021 and then spiked by 76.49% in 2022.
  • Over the past 5 years, Lineage Cell Therapeutics' Operating Income (Quarterly) stood at -$28.2 million in 2021, then skyrocketed by 76.49% to -$6.6 million in 2022, then grew by 4.17% to -$6.4 million in 2023, then climbed by 19.68% to -$5.1 million in 2024, then climbed by 1.41% to -$3.8 million in 2025.
  • Its last three reported values are -$3.8 million in Q3 2025, -$19.8 million for Q2 2025, and -$6.5 million during Q1 2025.